An observational study in Rectal Cancer and Lymph Node Metastasis, sponsored by Yanhong Deng. Enrolling by invitation. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-03-19.
Sponsored by Yanhong Deng · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Rectal Neoplasms by Yanhong Deng — 4 open to participants now, 4 under way, 1 of them phase 3. Rectal Neoplasms · Yanhong Deng.
Among the 11 studies in Rectal Neoplasms by Yanhong Deng, this one is the only one that started in 2014, is one of 7 observational ones, and was the 9th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →4 of the 11 studies in Rectal Neoplasms by Yanhong Deng are open now, in 1 country. Recruiting first, the newest first:
Yanhong Deng · Sites in China
Ages 18+
Yanhong Deng · Sites in China
Ages 18–75
Yanhong Deng · Sites in China
Ages 18–70
By country, each count listing its studies:
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,080 is above the median of 161 across 499 observational studies indexed under Rectal Neoplasms.
Median enrollment 426 across the 4 interventional studies, 458 across the 7 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Yanhong Deng is the lead sponsor of 16 studies on the registry; 7 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Rectal Neoplasms by Yanhong Deng, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
We evaluated all related clinical and pathologic data of patients with Locally Advanced Rectal Cancer following Neoadjuvant Chemoradiotherapy, including the pathologic regression grading in the primary tumor site and lymph node, and other histopathologic characteristics. Finally, the present study was aimed at (1) clarifying the clinical significance of the Major Pathologic Regression for Locally Advanced Rectal Cancer following Locally Advanced Rectal Cancer in the primary tumor site and lymph node, and (2) comparing different Neoadjuvant Chemoradiotherapy treatments of this uncommon disease through conducting a large, multi-center cohort study.
This large-scale, multi-center cohort study investigates the clinical significance of Pathologic Regression in lymph nodes (LNs) of patients with Locally Advanced Rectal Cancer (LARC) following Neoadjuvant Chemoradiotherapy (NCRT). Additionally, it compares the efficacy of diverse NCRT regimens in achieving pathologic regression and improving survival outcomes.
Study Design Type: Retrospective and prospective observational cohort study. Setting: Multi-center collaboration across 14 academic and community hospitals. Timeframe: Data from patients treated between 2014 and 2025 will be analyzed, with prospective follow-up ongoing until 2026.
Primary Objectives
Clarify the clinical significance of tumor regression in LN:
Define MPR thresholds for both primary tumor (e.g., ≤10% residual viable tumor) and lymph nodes (e.g., complete LN regression [ypN-Reg+] versus residual LN disease [ypN+]).
Correlate MPR status in the primary tumor and LNs with long-term outcomes:
Primary endpoints: Progression-Free Survival (PFS), Overall Survival (OS). Secondary endpoints: Local recurrence rate, distant metastasis-free survival.
Compare NCRT regimens:
Evaluate differences in MPR rates and survival outcomes between fluoropyrimidine-based, oxaliplatin-containing, and immunotherapy-augmented NCRT protocols.
Assess the impact of radiation dose escalation (e.g., 50.4 Gy vs. 45 Gy) on pathologic regression.
Study Population
Inclusion Criteria:
Adults (≥18 years) with histologically confirmed LARC (clinical stage II-III). Completion of NCRT followed by total mesorectal excision (TME). Availability of standardized pathologic reports and digitized whole-slide images (WSIs) for both primary tumor and LNs.
Exclusion Criteria:
Metastatic disease at diagnosis. Incomplete NCRT or surgical resection. Data Collection
Clinical Variables:
Demographics, NCRT regimen (drugs, doses, duration), surgical complications, adjuvant therapy, recurrence patterns.
Pathologic Variables:
Primary tumor: Residual viable tumor percentage, necrosis extent, tumor-infiltrating lymphocyte (TLS) density.
Lymph nodes: Regression grading (ypN-Reg+/-), number of regressed vs. metastatic LNs.
AI-driven quantitative analysis: Necrosis-to-tumor ratio (NECR-TD), TLS-to-necrosis ratio (T/NR), and spatial distribution of regressive features (Figure S2).
Imaging and Biomarkers:
Pre-treatment MRI-based tumor staging, post-treatment radiomic features (if available).
Statistical Analysis
Survival Analysis:
Kaplan-Meier curves and multivariable Cox regression to identify predictors of DFS/OS, adjusting for age, stage, and treatment regimen.
Subgroup analysis of LN regression (ypN-Reg+ vs. ypN-Reg-) in patients with ypN0 status.
Comparative Effectiveness:
Propensity score matching to balance baseline characteristics across NCRT regimens.
Meta-analysis of pooled multi-center data to assess heterogeneity in treatment effects.
Machine Learning:
Develop prognostic models integrating MPR status, histopathologic parameters, and clinical variables.
Ethical Considerations Approved by the Institutional Review Boards (IRBs) of all participating centers Innovation and Impact
Dual Focus on Primary Tumor and LNs:
First study to evaluate MPR thresholds simultaneously in primary tumor and LNs, addressing their independent prognostic roles.
Translational Insights:
Link LN regression to systemic immune responses (e.g., abscopal effect) and molecular heterogeneity between primary and metastatic sites.
Clinical Utility:
Provide evidence for standardizing MPR definitions in LARC and optimizing NCRT regimens based on tumor biology.
patients with Locally Advanced Rectal Cancer following Locally Advanced Rectal Cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Completion of NCRT followed by curative-intent surgery. Availability of pre- and post-treatment histopathologic data, including standardized regression grading and digitized whole-slide images (WSIs).
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PFS
Progression free survival
Time frame: 10 years
OS
Overall survival
Time frame: 10 years
No study locations are listed for this record.
Started Jan 2014 (actual). Primary completion is estimated for Dec 2025, 143 months after the start.
Of 214 non-industry observational studies under Rectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 118. This study's planned 143 months is above that.
Counting every sponsor, half of 229 studies reached it within 45 months; a quarter within 24 and three quarters within 116.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Yanhong Deng